InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a note issued to investors on Friday. The firm set a “sell” rating on the stock.

A number of other brokerages have also issued reports on NSPR. Piper Sandler reaffirmed an “overweight” rating and set a $4.50 target price on shares of InspireMD in a research report on Tuesday, September 17th. Lake Street Capital assumed coverage on shares of InspireMD in a research report on Wednesday, December 11th. They issued a “buy” rating and a $5.00 target price for the company.

InspireMD Stock Performance

NYSE:NSPR opened at $2.98 on Friday. The stock has a market cap of $77.73 million, a price-to-earnings ratio of -3.97 and a beta of 0.98. InspireMD has a 1 year low of $1.81 and a 1 year high of $3.42. The business has a fifty day moving average of $2.69 and a 200-day moving average of $2.69.

InspireMD (NYSE:NSPR) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. The firm had revenue of $1.81 million during the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. During the same period in the prior year, the firm posted ($0.15) earnings per share. On average, equities research analysts predict that InspireMD will post -0.79 EPS for the current year.

Hedge Funds Weigh In On InspireMD

An institutional investor recently bought a new position in InspireMD stock. Affiance Financial LLC purchased a new position in shares of InspireMD, Inc. (NYSE:NSPR) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned about 0.74% of InspireMD as of its most recent SEC filing. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.